Enwei Pharmaceutical Co

Enwei Pharmaceutical Co Current Liabilities

The Current Liabilities of Enwei Pharmaceutical Co (301331.SZ) as of Oct 21, 2026 is 59.05 M CNY. In the previous year, Current Liabilities was 109.80 M CNY — a change of -46.22% (lower).

Current Liabilities

59.05 MCNY

YoY

-46.22%

Last updated:

Current Liabilities of Enwei Pharmaceutical Co is 2025 59.05 M CNY. Current Liabilities of Enwei Pharmaceutical Co was 2024 109.80 M CNY. It decreases by -46.22% lower compared to the previous year.

The Enwei Pharmaceutical Co Current Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Liabilities
Date
Current Liabilities
Jan 1, 2019
111.17 M CNY
Jan 1, 2020
102.71 M CNY
Jan 1, 2021
88.33 M CNY
Jan 1, 2022
101.44 M CNY
Jan 1, 2023
82.26 M CNY
Jan 1, 2024
109.80 M CNY
Jan 1, 2025
59.05 M CNY
The Enwei Pharmaceutical Co Current Liabilities history
YEARCurrent LiabilitiesYoY
59.05 MCNY-46.22%
109.80 MCNY+33.48%
82.26 MCNY-18.91%
101.44 MCNY+14.84%
88.33 MCNY-14.00%
102.71 MCNY-7.61%
111.17 MCNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Enwei Pharmaceutical Co Stock analysis

What does Enwei Pharmaceutical Co do? Enwei Pharmaceutical Co., Ltd. generates revenue through the research, development, production, and sales of proprietary Chinese and chemical medicines. The company's main products include Jieeryin lotion, Jieeryin ointment, Jieeryin effervescent tablets, Shanmai Jianpi oral liquid, Qingjing capsules, and Danxiong Tongmai granules, which are primarily sold via direct sales and e-commerce channels. Its focus on gynecological products, pediatric medicines, and respiratory medicines targets domestic consumers seeking specialized healthcare solutions. The firm's domestic market strategy emphasizes direct customer engagement and online sales to reach its target segments. The company's product portfolio is tailored to specific health needs, with Jieeryin products addressing gynecological concerns, Shanmai Jianpi oral liquid supporting digestive health, Qingjing capsules for gynecological treatments, and Danxiong Tongmai granules targeting cardiovascular health. These offerings are distributed through direct sales teams and e-commerce platforms, aligning with the domestic market's preference for accessible healthcare products. Enwei's domestic focus ensures that its products meet local regulatory standards and consumer demands. Enwei Pharmaceutical's revenue streams are driven by the consistent demand for its specialized medicine categories, particularly in gynecology, pediatrics, and respiratory care. The firm's domestic market presence allows it to build strong relationships with healthcare providers and end-users, facilitating repeat purchases and brand loyalty. By concentrating on these key therapeutic areas, Enwei effectively serves its core customer segments without expanding into international markets. Enwei Pharmaceutical Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Enwei Pharmaceutical Co stock

Current Liabilities of Enwei Pharmaceutical Co is 59.05 M CNY in 2025.

Current Liabilities of Enwei Pharmaceutical Co changed from 109.80 M CNY to 59.05 M CNY, representing a -46.22% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Current Liabilities Enwei Pharmaceutical Co since 2006 – with annual values, charts, and detailed analysis.

Current liabilities are obligations due within one year, including accounts payable, short-term debt, and accrued expenses.

Current Liabilities's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Liabilities's Enwei Pharmaceutical Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Enwei Pharmaceutical Co

All Key Metrics — Enwei Pharmaceutical Co